The last twelve months at myDNA have been huge.
We’ve launched our new personalised wellness membership program, merged with US genomics giants, Gene by Gene, and we’re now entertaining the interest of a number of health tech SPACs (special purpose acquisition companies) out of the United States.
The DNA testing market is still emerging as a growing consumer market, particularly in the personalised wellness category.
The Australian Financial Review recently caught up with myDNA CEO, Lior Rauchberger, and myDNA Executive Chairman, Dennis Bastas, to discuss our recent growth, the merger with Gene by Gene, and how a potential SPAC listing might look for the company. An extract of the article is available below, or you can find the full article on their website.